Age group no. (%) | Total no. 60 | P value | ||||
---|---|---|---|---|---|---|
40—49 years | 50—59 years | 60—69 years | 70—79 years | |||
Residence of patient | ||||||
Central Sudan | 2 (10.5) | 12 (63.2) | 4 (21.1) | 1 (5.3) | 19 (31.7) | 0.550 |
East Sudan | 1 (16.7) | 5 (83.3) | 0 (0.0) | 0 (0.0) | 6 (10.0) | |
West Sudan | 6 (22.2) | 10 (37.0) | 9 (33.3) | 2 (7.4) | 27 (45.0) | |
North Sudan | 2 (25.0) | 3 (37.5) | 3 (37.5) | 0 (0.0) | 8 (13.3) | |
Site of cancer | ||||||
Cervix | 10 (19.6) | 25 (49.0) | 13 (25.5) | 3 (5.9) | 51 (85.0) | 0.885 |
Endometrium | 1 (20.0) | 3 (60.0) | 1 (20.0) | 0 (0.0) | 5 (8.3) | |
Ovary | 0 (0.0) | 2 (40.0) | 2 (40.0) | 0 (0.0) | 4 (6.7) | |
Cancer histological type | ||||||
SCC | 9 (20.0) | 22 (48.9) | 13 (28.9) | 1 (2.2) | 45 (75.0) | 0.330 |
Adenocarcinoma | 2 (13.0) | 8 (53.3) | 3 (20.0) | 2 (13.3) | 15 (25.0) | |
FIGO staging | ||||||
Stage 1 | 0 (0.0) | 2 (66.7) | 1 (33.3) | 0 (0.0) | 3 (5.0) | 0.279 |
Stage 2A | 1 (16.7) | 2 (33.3) | 3 (50.0) | 0 (0.0) | 6 (10.0) | |
Stage 2B | 5 (35.7) | 7 (50.0) | 2 (14.3) | 0 (0.0) | 14 (23.3) | |
Stage 3A | 1 (12.5) | 4 (50.0) | 3 (37.5) | 0 (0.0) | 8 (13.3) | |
Stage 3B | 2 (11.8) | 11 (64.7) | 2 (11.8) | 2 (11.8) | 17 (28.3) | |
Stage 4A | 0 (0.0) | 0 (0.0) | 2 (66.7) | 1 (33.3) | 3 (5.0) | |
Stage 4B | 2 (22.2) | 4 (44.4) | 3 (33.3) | 0 (0.0) | 9 (15.0) | |
Histopathological cancer grades | ||||||
Well differentiated SCC | 2 (16.7) | 5 (41.7) | 5 (41.7) | 0 (0.0) | 12 (20.0) | 0.633 |
Poorly differentiated SCC | 3 (15.0) | 10 (50.0) | 6 (30.0) | 1 (5.0) | 20 (33.3) | |
Moderately differentiated SCC | 4 (30.8) | 7 (53.8) | 2 (15.4) | 0 (0.0) | 13 (21.7) | |
Endometrium adenocarcinoma | 1 (9.1) | 6 (54.5) | 2 (18.2) | 2 (18.2) | 11 (18.3) | |
Endocervical adenocarcinoma | 1 (100) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.7) | |
Metastatic adenocarcinoma | 0 (0.0) | 1 (50.0) | 1 (50.0) | 0 (0.0) | 2 (3.3) | |
Ovarian mucinous cyst adenocarcinoma | 0 (0.0) | 1 (100) | 0 (0.0) | 0 (0.0) | 1 (1.7) |